Intellia Therapeutics (NASDAQ:NTLA) Upgraded to “Hold” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.

Several other research firms have also recently commented on NTLA. Wells Fargo & Company lowered their price target on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Oppenheimer set a $27.00 target price on shares of Intellia Therapeutics in a report on Friday, November 7th. Guggenheim downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. Robert W. Baird set a $9.00 price target on shares of Intellia Therapeutics in a report on Thursday, October 30th. Finally, JMP Securities dropped their price objective on Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating for the company in a report on Tuesday, October 28th. Ten research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Check Out Our Latest Stock Analysis on NTLA

Intellia Therapeutics Stock Performance

NTLA stock opened at $10.41 on Friday. The company has a 50 day moving average price of $9.44 and a two-hundred day moving average price of $12.70. The stock has a market capitalization of $1.21 billion, a P/E ratio of -2.44 and a beta of 2.05. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.34) EPS. Research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the sale, the executive vice president owned 98,533 shares of the company’s stock, valued at $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the sale, the chief executive officer owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. The trade was a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 53,051 shares of company stock valued at $488,600. Company insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Several large investors have recently bought and sold shares of the company. Schroder Investment Management Group lifted its holdings in Intellia Therapeutics by 1,593.4% in the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after buying an additional 382,425 shares in the last quarter. Voya Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 621.5% in the first quarter. Voya Investment Management LLC now owns 208,009 shares of the company’s stock worth $1,479,000 after acquiring an additional 179,180 shares in the last quarter. D.A. Davidson & CO. boosted its holdings in Intellia Therapeutics by 108.0% in the second quarter. D.A. Davidson & CO. now owns 54,120 shares of the company’s stock valued at $508,000 after purchasing an additional 28,100 shares during the last quarter. Marex Group plc acquired a new stake in Intellia Therapeutics during the 2nd quarter valued at approximately $5,849,000. Finally, JPMorgan Chase & Co. grew its stake in Intellia Therapeutics by 73.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock valued at $8,822,000 after purchasing an additional 396,858 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

Featured Articles